Key result
Addiction service referral reaches only ~5% of patients with substance-associated heart failure.
Why the study?
Reducing or stopping substance use can improve cardiac dysfunction in alcohol- and stimulant-associated cardiomyopathy, yet cardiology and addiction care are typically siloed, and little was known about addiction service referral patterns or engagement in this population.
Cohort (n=210)
No
Patients with alcohol- and stimulant-associated heart failure in a safety-net setting have a high burden of active substance use and psychiatric comorbidities, yet under 1% engage in addiction services, underscoring the need for integrated cardiology-addiction care models.
Answers are grounded in this paper and cite their sources.
Highlights gap in addiction service referral for substance-associated HF; leaves open whether integrated care models improve engagement and outcomes.
Background Alcohol- and stimulant-associated cardiomyopathy contribute to substantial morbidity and mortality. Reduction or cessation of substance use, alongside guideline-directed medical therapy, can improve—and sometimes reverse—cardiac dysfunction. Yet, cardiology and addiction care are typically siloed, and little is known about referral patterns or engagement in addiction services in this population. Methods We conducted a descriptive study of patients with alcohol- or stimulant-associated heart failure who attended at least 1 outpatient visit to a safety-net cardiology clinic between January 1 and December 31, 2022. Using electronic health record data and manual chart review, we identified demographic and clinical characteristics, co-occurring psychiatric and substance use disorders, and the outcomes of referrals to addiction services. Results Among 210 patients, the mean age was 58 years, 80% were male, and 33% experienced homelessness. Heart failure with reduced ejection fraction was the most common phenotype (45%). Current stimulant use was documented in 45% of patients and unhealthy alcohol use or alcohol use disorder in 40%; tobacco use was reported by 60%. Psychiatric comorbidities were prevalent, including depression (51%) and anxiety (39%). Despite high rates of substance use, only 10 patients (5%) were referred to addiction services, and just 2 (<1%) attended at least 1 appointment. Conclusions Patients with alcohol- and stimulant-associated cardiomyopathy experience high cardiovascular, psychiatric, and substance use morbidity yet extremely low engagement with addiction services. These findings highlight critical gaps in care and the urgent need for integrated, low-barrier models that bridge cardiology and addiction medicine.
No takes yet. Share an insight, caveat, or question.
Leyde et al. (2026) conducted a cohort in Alcohol- or stimulant-associated heart failure (n=210). Alcohol- or stimulant-associated heart failure in a safety-net cardiology clinic was evaluated on Referral to and attendance at addiction services. Among patients with alcohol- and stimulant-associated heart failure, only 5% were referred to addiction services and <1% attended an appointment.
Synapse has enriched 10 related papers. Consider them for comparative context: